

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07D 209/14, 401/12, 471/08, A61K 31/395		A1	(11) International Publication Number: WO 94/19320
		(43) International Publication Date: 1 September 1994 (01.09.94)	
(21) International Application Number: PCT/EP94/00438 (22) International Filing Date: 15 February 1994 (15.02.94) (30) Priority Data: 9303540.0 22 February 1993 (22.02.93) GB 9303843.8 25 February 1993 (25.02.93) GB (71) Applicant (for all designated States except US): MERCK SHARP & DOHME LIMITED [GB/GB]; Hertford Road, Hoddesdon, Hertfordshire EN11 9BU (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): KELLEHER, Fintan [IE/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). LEWIS, Richard, Thomas [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). MACLEOD, Angus, Murray [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). (74) Agent: HISCOCK, I., J.; Merck & Co., Inc., Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB).		(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report.	
(54) Title: AROMATIC COMPOUNDS, COMPOSITIONS CONTAINING THEM AND THEIR USE IN THERAPY			
<div style="text-align: center;"> <p>(I)</p> </div> <div style="display: flex; justify-content: space-around; margin-top: 20px;"> <div style="text-align: center;"> <p>(a)</p> </div> <div style="text-align: center;"> <p>(b)</p> </div> </div>			
(57) Abstract			
<p>The present invention relates to compounds of formula (I), and salts and prodrugs thereof, wherein Q¹ represents a phenyl group substituted by one or more halo, optionally substituted naphthyl, optionally substituted indolyl, optionally substituted benzthiophenyl, optionally substituted benzofuranyl, optionally substituted benzyl, or optionally substituted fluorenyl; R¹ represents H or C₁-alkyl; R² represents H, C₁-alkyl or C₂-alkenyl; Z¹ represents a group selected from (a) or (b). The compounds are tachykinin antagonists useful for treating pain or inflammation, migraine or emesis.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

AROMATIC COMPOUNDS, COMPOSITIONS CONTAINING THEM
AND THEIR USE IN THERAPY

5 This invention relates to a class of
heterocyclic compounds, which are useful as tachykinin
receptor antagonists.

 The tachykinins are a group of naturally-
occurring peptides found widely distributed throughout
10 mammalian tissues, both within the central nervous system
and in the peripheral nervous and circulatory systems.
The structures of three known mammalian tachykinins are
as follows:

Substance P:

15 Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH₂

Neurokinin A:

His-Lys-Thr-Asp-Ser-Phe-Val-Gly-Leu-Met-NH₂

Neurokinin B:

Asp-Met-His-Asp-Phe-Phe-Val-Gly-Leu-Met-NH₂

20 Substance P is believed inter alia to be involved in
the neurotransmission of pain sensations [Otsuka et al,
"Role of Substance P as a Sensory Transmitter in Spinal
Cord and Sympathetic Ganglia" in 1982 Substance P in the
Nervous System, Ciba Foundation Symposium 91, 13-34
25 (published by Pitman) and Otsuka and Yanagisawa, "Does
Substance P Act as a Pain Transmitter?" TIPS (Dec. 1987)
8 506-510], specifically in the transmission of pain in
migraine (B.E.B. Sandberg et al, J. Med Chem, (1982) 25
1009) and in arthritis [Levine et al in Science (1984)
30 226 547-549]. These peptides have also been implicated
in gastrointestinal (GI) disorders and diseases of the GI
tract such as inflammatory bowel disease [Mantyh et al in
Neuroscience (1988) 25 (3) 817-37 and D. Regoli in
"Trends in Cluster Headache" Ed. Sicuteri et al Elsevier

- 2 -

Scientific Publishers, Amsterdam (1987) page 85)] and
emesis [F.D. Tattersall et. al., Eur. J. Pharmacol.,
(1993) 250, R5-R6]. It is also hypothesised that there
is a neurogenic mechanism for arthritis in which
5 substance P may play a role [Kidd et al "A Neurogenic
Mechanism for Symmetrical Arthritis" in The Lancet, 11
November 1989 and Grönblad et al "Neuropeptides in
Synovium of Patients with Rheumatoid Arthritis and
Osteoarthritis" in J. Rheumatol. (1988) 15(12) 1807-10].
10 Therefore, substance P is believed to be involved in the
inflammatory response in diseases such as rheumatoid
arthritis and osteoarthritis [O'Byrne et al in Arthritis
and Rheumatism (1990) 33 1023-8]. Other disease areas
where tachykinin antagonists are believed to be useful
15 are allergic conditions [Hamelet et al Can. J. Pharmacol.
Physiol. (1988) 66 1361-7], immunoregulation [Lotz et al
Science (1988) 241 1218-21 and Kimball et al, J. Immunol.
(1988) 141 (10) 3564-9], vasodilation, bronchospasm,
reflex or neuronal control of the viscera [Mantyh et al,
20 PNAS (1988) 85 3235-9] and, possibly by arresting or
slowing β -amyloid-mediated neurodegenerative changes
[Yankner et al, Science (1990) 250, 279-82], in senile
dementia of the Alzheimer type, Alzheimer's disease and
Down's Syndrome.

25 Tachykinin antagonists may also be useful in the
treatment of small cell carcinomas, in particular small
cell lung cancer (SCLC) [Langdon et. al., Cancer Research
(1992) 52, 4554-7].

30 Substance P may also play a role in demyelinating
diseases such as multiple sclerosis and amyotrophic
lateral sclerosis [J. Lubner-Narod et. al., poster
presented at C.I.N.P. XVIIIth Congress, 28th June-2nd
July, 1992] and in disorders of bladder function such as

- 3 -

bladder detrusor hyper-reflexia (Lancet, 16th May, 1992, 1239).

It has furthermore been suggested that tachykinins have utility in the following disorders:

5 depression, dysthymic disorders, chronic obstructive airways disease, hypersensitivity disorders such as poison ivy, vasospastic diseases such as angina and Reynauld's disease, fibrosing and collagen diseases such as scleroderma and eosinophillic fascioliasis, reflex

10 sympathetic dystrophy such as shoulder/hand syndrome, addiction disorders such as alcoholism, stress related somatic disorders, neuropathy, neuralgia, disorders related to immune enhancement or suppression such as systemic lupus erythmatosis (European patent

15 specification no. 0 436 334), ophthalmic disease such as conjunctivitis, vernal conjunctivitis, and the like, and cutaneous diseases such as contact dermatitis, atropic dermatitis, urticaria, and other eczematoid dermatitis (European patent specification no. 0 394 989).


20 In view of their metabolic instability, peptide derivatives are likely to be of limited utility as therapeutic agents. It is for this reason that non-peptide tachykinin receptor antagonists are sought.

In essence, this invention provides a class of

25 potent non-peptide tachykinin receptor antagonists. By virtue of their non-peptide nature, the compounds of the present invention do not suffer from the shortcomings, in terms of metabolic instability, of known peptide-based tachykinin receptor antagonists.

30 The present invention provides a compound of formula (I), or a salt or prodrug thereof:

- 4 -



(I)

10 wherein


Q^1 represents a phenyl group substituted by one or more halo, optionally substituted naphthyl, optionally substituted indolyl, optionally substituted benzthiophenyl, optionally substituted benzofuranyl, optionally substituted benzyl, or optionally substituted fluorenyl;

R^1 represents H or C_{1-6} alkyl;

R^2 represents H, C_{1-6} alkyl or C_{2-6} alkenyl;

Z^1 represents a group selected from

20



where one of X^1 and Y^1 represents H and the other represents hydroxy or C_{1-6} alkoxy, or X^1 and Y^1 together form a group $=O$ or $=NOR^5$ where R^5 is H or C_{1-6} alkyl;

R^3 represents phenyl optionally substituted by 1, 2 or 3 groups selected from C_{1-6} alkyl, C_{1-6} alkenyl, C_{2-6} alkynyl, halo, cyano, nitro, trifluoromethyl,

30

- 5 -

trimethylsilyl, OR^a , SR^a , SOR^a , NR^aR^b , NR^aCOR^b , $NR^aCO_2R^b$, CO_2R^a or $CONR^aR^b$, where R^a and R^b independently represent H, C_{1-6} alkyl, phenyl or trifluoromethyl;

R^4 represents H or C_{1-6} alkyl;

5 the dotted line represents an optional covalent bond; and

 when Z^1 represents a group of formula (a), Z^2 represents C_{1-6} alkyl CO_2H , phenyl or phenyl C_{1-4} alkyl, wherein each phenyl moiety is substituted by CO_2H ; and

10 when Z^1 represents a group of formula (b), Z^2 represents a group of the formula $-X^2-Y^2-R^6$; where

X^2 represents a bond, O, S or NR^7 , where R^7 is H or C_{1-6} alkyl;

Y^2 represents a bond or C_{1-6} alkylidene; and

15 R^6 represents NR^cR^d (where R^c and R^d each independently represent H, C_{1-6} alkyl, phenyl or phenyl C_{1-4} alkyl wherein each phenyl moiety may be substituted by one or more of C_{1-6} alkyl, C_{1-6} alkoxy, halo or trifluoromethyl) or an optionally substituted aromatic
20 or non-aromatic azacyclic or azabicyclic group.

 As used herein, the definition of each expression, when it occurs more than once in any structure, is intended to be independent of its definition elsewhere in the same structure.

25 The alkyl, alkenyl and alkynyl groups referred to with respect to any of the above formulae may represent straight, branched or cyclic groups or combinations thereof. Thus, for example, suitable alkyl groups include methyl, ethyl, n- or iso-propyl, n-, sec-,
30 iso- or tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, and cycloalkyl-alkyl groups such as cyclopropylmethyl; suitable alkenyl groups include vinyl and allyl; and suitable alkynyl groups include propargyl.

- 6 -

For the avoidance of doubt, when the covalent bond represented by the dotted line is present, the compounds of formula (I) contain an olefinic double bond.

When Y^2 represents C_{2-6} alkylidene, it may be a straight or a branched chain.

The term "halo" as used herein includes fluoro, chloro, bromo and iodo, especially chloro and fluoro.

Where Q^1 represents optionally substituted fluorenyl, the group is linked through the bridgehead carbon atom, that is to say, C-9 of the fluorenyl moiety.

Where Q^1 represents optionally substituted naphthyl, indolyl, benzothiophenyl, benzofuranyl, benzyl or fluorenyl, suitable substituents include C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, SR^a , SOR^a , SO_2R^a , OR^a , NR^aR^b , NR^aCOR^b , NR^aCOOR^b , $COOR^a$ or $CONR^aR^b$, where R^a and R^b are as above defined. One or more substituents may be present and each may be located at any available ring position, except, where Q^1 is optionally substituted indolyl, the nitrogen atom. Where Q^1 is optionally substituted indolyl, suitable nitrogen substituents include C_{1-6} alkyl, optionally substituted phenyl(C_{1-4} alkyl), $COOR^a$ or $CONR^aR^b$, wherein R^a and R^b are as above defined.

Suitable values of the group Q^1 include 3,4-dichlorophenyl, 3-indolyl, 2-naphthyl, 3-naphthyl, 9-fluorenyl, benzyl, 3-benzothiophenyl and 3-benzofuranyl.

Preferably Q^1 is 3-indolyl, 3-benzothiophenyl or 3,4-dichlorophenyl, more preferably 3-indolyl.

Suitably R^1 represents H or methyl, preferably H.

Preferably R^2 represents H or methyl, more preferably H.

- 7 -

Where Z^1 represents a group of formula (a), preferably the double bond is absent.

Suitably one of X^1 and Y^1 represents hydroxy or C_{1-6} alkoxy, such as methoxy, or X^1 and Y^1 together represent =O or =NOH. Preferably one of X^1 and Y^1 represents methoxy or X^1 and Y^1 together represent =O. More preferably, X^1 and Y^1 together represent =O.

When Z^2 represents C_{1-6} alkylCO₂H, it will preferably represent C_{1-3} alkylCO₂H, such as (CH₂)₂CO₂H.

When Z^2 represents phenyl substituted by CO₂H, substitution in the para position is preferred.

Where Z^1 represents a group of formula (b), preferably R^4 is H.

Preferably X^2 represents a bond, O or NH.

In one preferred subgroup of compounds according to the invention X^2 represents a bond and Y^2 represents CH₂.

Where Z^1 represents either a group of formula (a) or a group of formula (b), preferably R^3 represents substituted phenyl. Suitable phenyl substituents include nitro, trifluoromethyl, trimethylsilyl, bromo, chloro, fluoro, iodo, cyano, methyl, ethyl, cyclopropyl, vinyl, methoxy, phenoxy and amino. Preferably R^3 represents disubstituted phenyl.

Particularly preferred are compounds wherein R^3 represents 3,5-bis(trifluoromethyl)phenyl.

Where Z^2 represents a group of the formula $-X^2-Y^2-R^6$, the aromatic or non-aromatic azacycle or azabicyclic R^6 may contain one or more additional heteroatoms selected from O and S, or groups NR⁷, where R^7 is H or C_{1-6} alkyl, and may be unsubstituted or substituted. Suitable substituents include C_{1-6} alkyl, C_{1-6} alkoxy, oxo, SH, =S, halo, trifluoromethyl, NR^aR^b,

- 8 -


NR^aCOR^b , CONR^aR^b , CO_2R^a and CH_2OR^a , where R^a and R^b are as previously defined.

When R^6 represents NR^cR^d , R^c and R^d are suitably selected from H and C_1 - 6 alkyl, such as C_1 - 4 alkyl, e.g. methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl and t-butyl.

When R^6 represents an aromatic azacycle or azabicyclo, suitable values of R^6 include imidazolyl, triazolyl, tetrazolyl, oxazolyl, thiazolyl, pyrrolyl, pyrazolyl, pyrazinyl, pyridyl, oxadiazolyl, thiadiazolyl, isoxazolyl, isothiazolyl, benzimidazolyl, benzoxazolyl and indolyl, preferably imidazolyl, such as 2,4-imidazolyl, or pyridyl, more preferably pyridyl such as 4-, 3- or 2-pyridyl.

When R^6 represents a non-aromatic azacycle or azabicyclo, suitable values of R^6 include morpholinyl, piperdinyl, pyrrolidinyl, piperazinyl, methylpiperazinyl, azanorbornanyl, azabicyclo[2.2.2]octanyl and azabicyclo[3.2.2]nonyl, preferably morpholinyl, methylpiperazinyl, quinuclidinyl (azabicyclo[2.2.2]octanyl) or azabicyclo[3.2.2]nonyl.

According to a second or further aspect of the present invention, there is provided a compound of formula (Ia) or a salt or prodrug thereof:



(Ia)

wherein

- 9 -

Q^1 represents a phenyl group substituted by one or more halo; optionally substituted naphthyl; optionally substituted indolyl; optionally substituted benzthiophenyl; optionally substituted benzofuranyl; optionally substituted benzyl; or optionally substituted fluorenyl;

the dotted line represents an optional covalent bond;

one of X^1 and Y^1 represents H and the other represents hydroxy or C_{1-6} alkoxy, or X^1 and Y^1 together form a group $=O$ or $=NOR^5$ where R^5 is H or C_{1-6} alkyl;


R^1 represents H or C_{1-6} alkyl;

R^2 represents H, C_{1-6} alkyl or C_{2-6} alkenyl;

R^3 represents phenyl optionally substituted by 1, 2, or 3 groups selected from C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, OR^a , SR^a , SOR^a , NR^aR^b , NR^aCOR^b , $NR^aCO_2R^b$, CO_2R^a or $CONR^aR^b$, where R^a and R^b independently represent H, C_{1-6} alkyl, phenyl or trifluoromethyl; and

Z^2 represents C_{1-6} alkyl CO_2H , phenyl or phenyl C_{1-4} alkyl, wherein each phenyl moiety is substituted by CO_2H .

According to a further or alternative aspect of the present invention, there is provided a compound of formula (Ib) or a salt or prodrug thereof:



(Ib)

- 10 -

wherein

Q^1 represents a phenyl group substituted by one or more halo, optionally substituted naphthyl, optionally substituted indolyl, optionally substituted benzthiophenyl, optionally substituted benzofuranyl, optionally substituted benzyl or optionally substituted fluorenyl;

X^2 represents a bond, O, S or NR^7 ;

Y^2 represents a bond or C_{1-6} alkylidene;

10 R^1 represents H or C_{1-6} alkyl;

R^2 represents H, C_{1-6} alkyl or C_{2-6} alkenyl;

15 R^3 represents phenyl optionally substituted by 1, 2, or 3 groups selected from C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, OR^a , SR^a , SOR^a , NR^aR^b , NR^aCOR^b , $NR^aCO_2R^b$, CO_2R^a or $CONR^aR^b$, where R^a and R^b independently represent H, C_{1-6} alkyl, phenyl or trifluoromethyl;

R^4 represents H or C_{1-6} alkyl;


R^5 represents H or C_{1-6} alkyl; and

20 R^6 represents NR^cR^d (where R^c and R^d each independently represent H, C_{1-6} alkyl or phenyl C_{0-4} alkyl optionally substituted in the phenyl ring by one or more of C_{1-6} alkyl, C_{1-6} alkoxy, halo or trifluoromethyl) or an optionally substituted aromatic or non-aromatic azacyclic or azabicyclic group.

25 A particular subgroup of compounds according to the invention is represented by compounds of formula (Ic), and salts and prodrugs thereof:

30

- 11 -



(Ic)

wherein R^2 , X^1 and Y^1 are as defined for formula (I);
the dotted line represents an optional covalent bond;

Z^2 represents C_{1-6} alkyl CO_2H , phenyl or
15 phenyl C_{1-4} alkyl, wherein each phenyl moiety is
substituted by CO_2H ;

Z^3 represents O, S or NR^{14} (where R^{14} is H,
 C_{1-6} alkyl, optionally substituted phenyl(C_{1-4} alkyl),
 CO_2R^a or $CONR^aR^b$, where R^a and R^b are as previously
20 defined), preferably S or NH;


R^{11} and R^{12} each independently represent H,
 C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halo, cyano, nitro,
trifluoromethyl, trimethylsilyl, OR^a , SR^a , SOR^a , NR^aR^b ,
 NR^aCOR^b , $NR^aCO_2R^b$, CO_2R^a or $CONR^aR^b$, where R^a and R^b are
25 as previously defined;

each R^{13} may occupy any available carbon atom
of the bicyclic ring system and independently represents
 C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halo, cyano, nitro,
trifluoromethyl, trimethylsilyl, OR^a , SR^a , SOR^a , NR^aR^b ,
30 NR^aCOR^b , $NR^aCO_2R^b$, CO_2R^a or $CONR^aR^b$, where R^a and R^b are
as previously defined; and

q is 0, 1, 2 or 3, preferably 0.

- 12 -

Another particular sub-group of compounds according to the invention is represented by compounds of formula (Id), and salts and prodrugs thereof:



(Id)

wherein X^2 and Y^2 are as defined for formula (I);

Z^2 represents O, S or NR^{14} (where R^{14} is H,

15 C_{1-6} alkyl, optionally substituted phenyl(C_{1-4} alkyl), CO_2R^a or $CONR^aR^b$, where R^a and R^b are as previously defined), preferably S or NH;

R^{10} is imidazolyl, triazolyl, tetrazolyl, oxazolyl, thiazolyl, pyrrolyl, pyrazolyl, pyrazinyl, pyridyl, oxadiazolyl, thiadiazolyl, isoxazolyl, isothiazolyl, benzimidazolyl, benzoxazolyl, indolyl, morpholinyl, piperdiny, pyrrolidinyl, piperazinyl, methylpiperazinyl, azanorboranyl, azabicyclo[2.2.2]octanyl or azabicyclo[3.2.2]nonyl, preferably imidazolyl, pyridyl, morpholinyl, methylpiperazinyl, azabicyclo[2.2.2]octanyl or azabicyclo[3.2.2]nonyl;

25 R^{11} and R^{12} each independently represent H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, chloro, bromo, fluoro, iodo, cyano, nitro, trifluoromethyl, trimethylsilyl, OR^a , SR^a , SOR^a , NR^aR^b , NR^aCOR^b , $NR^aCO_2R^b$, CO_2R^a or $CONR^aR^b$, where R^a and R^b are as previously defined;

- 13 -

each R^{13} may occupy any available carbon atom of the bicyclic ring system and independently represents C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, OR^a , SR^a , SOR^a , NR^aR^b , NR^aCOR^b , $NR^aCO_2R^b$, CO_2R^a or $CONR^aR^b$, where R^a and R^b are as previously defined; and

q is 0, 1, 2 or 3, preferably 0.

For use in medicine, the salts of the compounds of formula (I) will be pharmaceutically acceptable salts. Other salts may, however, be useful in the preparation of the compounds according to the invention or of their pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, oxalic acid, fumaric acid, p-toluenesulphonic acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid. Salts of amine groups may also comprise quaternary ammonium salts in which the amino nitrogen atom carries a suitable organic group such as an alkyl, alkenyl, alkynyl or aralkyl moiety. Thus, for example, when R^1 or R^5 is other than H, the nitrogen atom to which it is attached may be further substituted to give a quaternary ammonium salt. Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include metal salts such as alkali metal salts, e.g. sodium or potassium salts; and alkaline earth metal salts, e.g. calcium or magnesium salts.

The present invention includes within its scope prodrugs of the compounds of formula (I) above. In

- 14 -

general, such prodrugs will be functional derivatives of the compounds of formula (I) which are readily convertible in vivo into the required compound of formula (I). Conventional procedures for the selection and
5 preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.

The compounds according to the invention may exist both as enantiomers and as diastereomers. It is to
10 be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention.

Specific compounds within the scope of the present invention include:

15 N-(5-(3,5-bis(trifluoromethyl)phenyl)-1-(3-indolyl)-3-pentanone-2-yl)-succinamic acid;
5-(3,5-bis(trifluoromethyl)phenyl)-2-(4-carboxybutyramido)-1-(3-indolyl)-3-pentanone;
5-(3,5-bis(trifluoromethyl)phenyl)-2-(6-carboxyhexanamido)-1-(3-indolyl)-3-pentanone;
20 5-(3,5-bis(trifluoromethyl)phenyl)-2-(4-carboxybenzamido)-1-(3-indolyl)-3-pentanone;
5-(3,5-bis(trifluoromethyl)phenyl)-2-(2-carboxybenzamido)-1-(3-indolyl)-3-pentanone;
25 5-(3,5-bis(trifluoromethyl)phenyl)-2-(3-carboxybenzamido)-1-(3-indolyl)-3-pentanone;
N-(3,5-bis(trifluoromethyl)benzyl)-2-((4-pyridyl)acetamido)-3-(3-indolyl)propionamide;
N-(3,5-bis(trifluoromethyl)benzyl)-2-((3-pyridyl)acetamido)-3-(3-indolyl)propionamide;
30 N-(3,5-bis(trifluoromethyl)benzyl)-N-methyl-2-(3-(3-pyridyl)propionamido)-3-(3-indolyl)propionamide;

- 15 -

N-(3,5-bis(trifluoromethyl)benzyl)-N-methyl-2-(4-(1-(1-azabicyclo[2.2.3]nonyl))butyramido)-3-(3-indolyl)propionamide;
and salts and prodrugs thereof.

5 The invention also provides pharmaceutical compositions comprising one or more compounds of this invention in association with a pharmaceutically acceptable carrier. Preferably these compositions are in unit dosage forms such as tablets, pills, capsules,
10 powders, granules, solutions or suspensions, or suppositories, for oral, parenteral or rectal administration, or administration by inhalation or insufflation.

 For preparing solid compositions such as
15 tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other
20 pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a non-toxic pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as
25 homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation composition is then
30 subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention. The tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the

- 16 -

advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by
5 an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of
10 polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.

The liquid forms in which the novel compositions of the present invention may be incorporated
15 for administration orally or by injection include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical
20 vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinylpyrrolidone or gelatin.

25 Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable
30 excipients as set out above. Preferably the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions in preferably sterile pharmaceutically acceptable solvents may be nebulised by use of inert gases. Nebulised solutions may

- 17 -

be breathed directly from the nebulising device or the nebulising device may be attached to a face mask, tent or intermittent positive pressure breathing machine.

5 Solution, suspension or powder compositions may be administered, preferably orally or nasally, from devices which deliver the formulation in an appropriate manner.

The present invention further provides a process for the preparation of a pharmaceutical composition comprising a compound of formula (I), which process comprises bringing a compound of formula (I) into
10 association with a pharmaceutically acceptable carrier or excipient.

The compounds of formula (I) are of value in the treatment of a wide variety of clinical conditions
15 which are characterised by the presence of an excess of tachykinin, in particular substance P, activity. These may include disorders of the central nervous system such as anxiety, depression, psychosis and schizophrenia; epilepsy; neurodegenerative disorders such as dementia,
20 including senile dementia of the Alzheimer type, Alzheimer's disease and Down's syndrome; demyelinating diseases such as MS and ALS and other neuropathological disorders such as peripheral neuropathy, including diabetic and chemotherapy-induced neuropathy, and
25 postherpetic and other neuralgias; small cell carcinomas such as small cell lung cancer; respiratory diseases, particularly those associated with excess mucus secretion such as chronic obstructive airways disease, bronchopneumonia, chronic bronchitis, cystic fibrosis and
30 asthma, and bronchospasm; inflammatory diseases such as inflammatory bowel disease, psoriasis, fibrositis, osteoarthritis and rheumatoid arthritis; allergies such as eczema and rhinitis; hypersensitivity disorders such as poison ivy; ophthalmic diseases such as

- 18 -

conjunctivitis, vernal conjunctivitis, and the like;
cutaneous diseases such as contact dermatitis, atropic
dermatitis, urticaria, and other eczematoid dermatitis;
addiction disorders such as alcoholism; stress related
5 somatic disorders; reflex sympathetic dystrophy such as
shoulder/hand syndrome; dysthymic disorders; adverse
immunological reactions such as rejection of transplanted
tissues and disorders related to immune enhancement or
suppression such as systemic lupus erythematosus;
10 gastrointestinal (GI) disorders and diseases of the GI
tract such as disorders associated with the neuronal
control of viscera such as ulcerative colitis, Crohn's
disease and incontinence; emesis, including acute,
delayed and anticipatory emesis, for example, induced by
15 chemotherapy, radiation, toxins, pregnancy, vestibular
disorders, surgery, migraine and variations in
intercranial pressure; disorders of bladder function such
as bladder detrusor hyper-reflexia; fibrosing and
collagen diseases such as scleroderma and eosinophilic
20 fascioliasis; disorders of blood flow caused by
vasodilation and vasospastic diseases such as angina,
migraine and Reynaud's disease; and pain or nociception,
for example, that attributable to or associated with any
of the foregoing conditions, especially the transmission
25 of pain in migraine.

The compounds of formula (I) are also of value
in the treatment of a combination of the above
conditions, in particular in the treatment of combined
post-operative pain and post-operative nausea and
30 vomiting.

The compounds of formula (I) are particularly
useful in the treatment of pain or nociception and/or
inflammation and disorders associated therewith such as,
for example, neuropathy, such as diabetic and

- 19 -

chemotherapy-induced neuropathy, postherpetic and other neuralgias, asthma, osteoarthritis, rheumatoid arthritis and especially migraine.

The present invention further provides a
5 compound of formula (I), or a salt or prodrug thereof, for use in therapy.


In the treatment of conditions involving actions of tachykinins released physiologically in response to noxious or other stimuli, a suitable dosage
10 level is about 0.001 to 50 mg/kg per day, preferably about 0.005 to 10 mg/kg per day, and especially about 0.005 to 5 mg/kg per day. The compounds may be administered on a regimen of 1 to 4 times per day, preferably once daily.

15 According to a further or alternative aspect, the present invention provides a method of treatment of a human or animal subject suffering from or susceptible to a condition characterised by the presence of an excess of tachykinins, especially substance P, which method
20 comprises administering to a human or animal subject in need of such treatment an effective amount of a compound of formula (I), or a salt or prodrug thereof.

The present invention also provides the use of a compound of formula (I), or a salt or prodrug thereof,
25 for the manufacture of a medicament for the treatment of conditions characterised by the presence of an excess of tachykinins, especially substance P.

Compounds of formula (I) wherein Z^1 represents a group of formula (a) may be prepared from intermediates
30 of formula (II):

- 20 -




wherein Q^1 , R^1 , R^2 , R^3 , X^1 , Y^1 and --- are as defined for formula (I), by reaction with a reagent suitable to introduce the group COZ^2 where Z^2 represents $C_{1-6}alkylCO_2H$, phenyl or phenyl $C_{1-4}alkyl$, wherein each phenyl moiety is substituted by CO_2H .

Suitable reagents will be readily apparent to those skilled in the art and include, for example, suitable carboxylic acid anhydrides and esters of formula Z^2CO-OR^{30} , where R^{30} is alkyl, such as $C_{1-4}alkyl$, e.g. ethyl. The reaction is conducted in the presence of a base, such as a tertiary amine, for example, triethylamine, preferably in the presence of an acylation catalyst such as, for example, 4-dimethylaminopyridine. The reaction is conveniently effected in a suitable organic solvent, such as, for example, a halogenated hydrocarbon, e.g. dichloromethane, or dimethyl formamide.

Acid anhydrides and esters of formula Z^2CO-OR^{30} are commercially available or may be prepared by conventional methods, for example, as described in the accompanying examples or in *Helv. Chim. Acta*, 57, 2332 (1974).

Intermediates of formula (II) wherein X^1 and Y^1 together represent $=O$ and the double bond is present may be prepared by reaction of an aldehyde of formula R^3CHO with a compound of formula (III):

- 21 -



(III)

wherein Q^1 , R^1 and R^2 are as defined for formula (I) and
 10 R^{20} represents a group PR^{X}_3 or $\text{PO}(\text{OR}^{\text{X}})_2$, wherein R^{X}
 represents phenyl or C_{1-10} alkyl, in the presence of a
 base.

Suitable bases include alkali metal hydrides,
 such as, for example, sodium hydride, alkali metal
 15 carbonates, such as, for example, potassium carbonate,
 and strong organic bases such as, for example, 1,8-
 diazabicyclo[5.4.0] undec-7-ene in the presence of
 anhydrous lithium chloride.

The reaction is conveniently effected in a
 20 suitable organic solvent, such as an ether, e.g.
 tetrahydrofuran, or acetonitrile, suitably at ambient
 temperature.

Compounds of formula (II) wherein one of X^1 and
 Y^1 represents H and the other represents hydroxy may be
 25 prepared from the corresponding compounds of formula (II)
 wherein X^1 and Y^1 together represent $=\text{O}$, by reduction.

Suitable reducing agents include, for example,
 hydride reducing agents such as lithium aluminium hydride
 and sodium borohydride.

30 The reaction is conveniently carried out in a
 suitable organic solvent, such as an ether, e.g.
 tetrahydrofuran, suitably at ambient temperature.

Compounds of formula (II) wherein one of X^1 and
 Y^1 represents H and the other represents C_{1-6} alkoxy may

- 22 -

be prepared from the corresponding compounds of formula (II) wherein one of X^1 and Y^1 represents H and the other represents hydroxy, by alkylation.

Suitable alkylation procedures include
5 treatment of an alcohol of formula (II) with an alkali metal hydride, such as sodium hydride, and a C_{1-6} alkylhalide. Suitable halides include, in particular, bromides and iodides.

The reaction is conveniently effected in an
10 anhydrous organic solvent, for example, an ether, e.g. dimethoxyethane, suitably at ambient temperature.

Compounds of formula (II) wherein X^1 and Y^1 together represent $=NOR^5$ may be prepared from the corresponding compounds of formula (II) wherein X^1 and Y^1
15 together represent $=O$ by the addition of hydroxylamine, or a derivative thereof. Compounds wherein R^5 is other than H may be prepared from the corresponding compounds wherein R^5 is H by alkylation, for example, using a diazo compound, such as diazomethane, or an alkyl halide or
20 sulphate.


Compounds of formula (II) wherein the double bond is absent may be prepared from the corresponding unsaturated compounds of formula (II) by reduction.

Suitable reduction procedures include catalytic
25 hydrogenation. Suitable hydrogenation catalysts include noble metals, for example, platinum or palladium, or oxides thereof, which may be supported, for example, on charcoal. A preferred catalyst is Wilkinson's catalyst (tris(triphenylphosphine)rhodium(I)chloride).

30 The reaction is conveniently effected in a suitable organic solvent, such as an ether, e.g. tetrahydrofuran, an alcohol, e.g. ethanol, or an ester, e.g. ethyl acetate, suitably at ambient temperature.

- 23 -

Compounds of formula (III) may be prepared from compounds of formula (IV)



(IV)

wherein Q^1 , R^1 and R^2 are as defined for formula (I) and R^{21} represents an alkoxy or a suitably substituted amino group, such as a group NR^YOR^Z , where R^Y and R^Z represent alkyl, in particular a group $\text{NCH}_3(\text{OCH}_3)$, by reaction with
 15 a compound of formula $\text{CH}_3\text{PO}(\text{OR}^X)_2$, where R^X is an alkyl group, in the presence of a base.


Suitable reaction procedures will be readily apparent to the skilled person and examples thereof are described in the accompanying Examples.

20 Suitable bases of use in the reaction include alkyl lithiums, such as butyl lithiums.


Compounds of formula (IV) are commercially available or may be prepared using standard procedures well known to the skilled person in the art. The
 25 compounds of formula (IV) are amino acid derivatives. Syntheses of amino acids and derivatives thereof are well documented and are described, for example, in Chemistry and Biochemistry of the Amino Acids, ed. G. C. Barrett, Chapman and Hall, 1985.

30 Compounds of formula (I) wherein Z^1 represents a group of formula (b) and Z^2 is the group $-\text{X}^2-\text{Y}^2-\text{R}^6$ wherein X^2 represents O, S or NR^7 may be prepared by reaction of intermediates of formula (V) with compounds of formula (VI):

- 24 -



(V)



(VI)

wherein Q^1 , R^1 , R^2 , R^3 , R^4 , R^6 , X^2 and Y^2 are as defined
 10 for formula (I), and one of R^{22} and R^{23} represents a
 group CO-A, where A represents an activating group, and
 the other of R^{22} and R^{23} represents H, in the presence of
 a base.

Suitable activating groups represented by A
 15 include phenoxy substituted by one or more electron-
 withdrawing substituents. A preferred activating group
 is 4-nitrophenoxy.

Suitable bases of use in the reaction include
 tertiary amines such as, for example, triethylamine, or
 20 dimethylaminopyridine (DMAP).

When X^2 represents NR^7 , R^{22} preferably
 represents CO-A and R^{23} preferably represents H.

When X^2 represents O or S, R^{22} preferably
 represents H and R^{23} preferably represents CO-A.

25 Alternatively, compounds of formula (I) wherein
 X^2 is NH may be prepared from intermediates of formula
 (V) wherein R^{22} is H (hereinafter intermediates (VA)) by
 reaction with an isocyanate of formula $R^6(CH_2)_nN=C=O$,
 where n is zero or an integer from 1 to 6.

30 The reaction is conveniently effected in a
 suitable organic solvent such as an ether, for example,
 tetrahydrofuran.


Compounds of formula (I) wherein X^2 represents
 a bond may be prepared from intermediates of formula (VA)

- 25 -

by reaction with a reagent suitable to introduce the group $\text{CO-X}^2\text{-Y}^2\text{-R}^6$.

Suitable reagents will be readily apparent to those skilled in the art and include, for example, carboxylic acids of formula $\text{R}^6\text{-Y}^2\text{-X}^2\text{-COOH}$ and acyl halides of formula $\text{R}^6\text{-Y}^2\text{-X}^2\text{-COHal}$, where Hal is halo, such as chloro, bromo or iodo. The reaction is preferably conducted in the presence of a base, such as a tertiary amine, for example, triethylamine, conveniently in a suitable organic solvent, such as, for example, dimethyl formamide.

Compounds of formula (V) wherein R^{22} is an activating group (hereinafter intermediates (VB)) may be prepared from corresponding compounds of formula (VA) by reaction with a compound of formula (VII)



(VII)

wherein A represents an activating group, such as a phenyl group bearing one or more electron-withdrawing substituents, for example, 4-nitrophenyl, and Hal represents halo, such as chloro or bromo, in the presence of a base.

Suitable bases of use in the reaction include tertiary amines, such as, for example, triethylamine.


Compounds of formula (VI) wherein R^{23} is an activating group may be prepared from corresponding compounds of formula (VI) wherein R^{23} is H, by reaction with a compound of formula (VII) in the presence of a

- 26 -

base, such as a tertiary amine, for example, triethylamine or DMAP.

Acids and acyl halides of formulae $R^6-Y^2-X^2-COOH$ and $R^6-Y^2-X^2-COHal$ are commercially available or may be prepared by conventional methods, for example, as described in the accompanying examples or in Helv. Chim. Acta, 57, 2332 (1974).

The preparation of intermediates of formula (VA) is described in W093/01169. Thus intermediates of formula (VA) may be prepared by reaction of an amino acid of formula (VIII)



(VIII)

wherein Q¹, R¹ and R² are as defined for formula (I), in a suitably protected form, with an amine of formula HNR⁴-CH₂R³, wherein R³ and R⁴ are as defined for formula (I).

The reaction is suitably effected in the presence of a base, such as a tertiary amine, for example, triethylamine, preferably in the presence of a suitable alkylchloroformate, such as t-butylchloroformate, conveniently in a suitable organic solvent, such as a halogenated hydrocarbon, e.g. dichloromethane. Alternatively, the reaction may be effected in the presence of a coupling agent, such as dicyclohexylcarbodiimide.

Compounds of formula (VIII) are commercially available or may be prepared using standard syntheses.

- 27 -

Syntheses of amino acids are well documented and are described, for example, in Chemistry and Biochemistry of the Amino Acids, ed. G. C. Barrett, Chapman and Hall, 1985.

5 Where the above-described processes for the preparation of the compounds according to the invention give rise to mixtures of stereoisomers, these isomers may be separated, suitably by conventional techniques such as preparative chromatography.

10 The novel compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution. The novel compounds may, for example, be resolved into their component enantiomers by standard techniques, such as the
15 formation of diastereomeric pairs by salt formation with an optically active acid, such as (-)-di-p-toluoyl-d-tartaric acid and/or (+)-di-p-toluoyl-l-tartaric acid followed by fractional crystallization and regeneration of the free base. The novel compounds may also be
20 resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary.

 During any of the above synthetic sequences it may be necessary and/or desirable to protect sensitive or
25 reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene and P.G.M. Wuts, Protective Groups in
30 Organic Synthesis, John Wiley & Sons, 1991. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.

 The exemplified compounds of this invention were tested by the methods set out at pages 29 to 30 of

- 28 -

European Patent Specification No. EP-A-0 528 495. The compounds were found to be active with IC_{50} at the NK1 receptor of less than 150nM.

5 The compounds of this invention may be formulated as specifically illustrated at pages 28 to 29 of European Patent Specification No. EP-A-0 528 495.

The following non-limiting Examples illustrate the preparation of compounds according to the invention.

EXAMPLE 1N-(5-(3,5-Bistrifluoromethylphenyl)-1-(3-indolyl)-3-keto-pent-2-yl)-succinamic acid Sodium salt

5

(a) N-Methoxy-N-methyl 2-t-butyloxycarbonylamino-3-(3-indolyl)propionamide

10 N- α -BOC-L-tryptophan (100g) was dissolved in dimethyl formamide (800ml) and triethylamine (101g) was added. The reaction was cooled to -30°C and isobutyl chloroformate (42.5ml) was added, maintaining the internal temperature to below -20°C. The reaction was stirred for 15 minutes before adding

15 N,O-dimethyl hydroxylamine hydrochloride (64g) and then diluting the reaction with dichloromethane (1l), maintaining the internal temperature below 0°C. The reaction was stirred for 15 minutes, poured into ethyl acetate (3l) and washed with 10% citric acid (1l), water (3x 1l), saturated sodium bicarbonate (1l) and water (1l). The organic phase was dried (MgSO₄), filtered,

20 and evaporated until crystallisation ensued. The suspension was diluted with petroleum ether, filtered and dried to yield the title compound; mp = 129-130°C; ¹H NMR (360MHz, D₆ DMSO) δ 10.80 (1H, s); 7.51 (1H, d, J = 7Hz); 7.33 (1H, d, J = 7Hz); 7.16 (1H, s); 7.08-6.97 (3H, m); 4.62-4.58 (1H, m); 3.72 (3H, s); 3.34

25 (3H, s); 3.02-2.81 (2H, m); 1.31 (9H, s).

(b) 2-t-Butyloxycarbonylamino-1-(3-indolyl)-4-dimethyl-phosphono-3-butanone

Dimethyl methane phosphonate (205g) was dissolved in
5 tetrahydrofuran (800ml), cooled to -70°C; and then treated with
n-butyllithium (1.6M in hexane, 900ml), maintaining the
internal temperature of the reaction at below -55°C. The
reaction was stirred for one hour before adding the product of
part (a) (90g). The reaction was stirred at -70°C for 30 minutes
10 before quenching with saturated ammonium chloride. The
resulting mixture was extracted with ethyl acetate and the
organic extract was washed with water (5 x 500ml), dried
(MgSO₄) and evaporated. The residue was purified on silica
(eluting with ethyl acetate) to yield the title compound as an oil;
15 ¹H NMR (360MHz, CDCl₃) δ 10.84 (1H, s), 7.56 (1H, d, J =
7Hz), 7.33 (1H, d, J = 7Hz), 6.98 (1H, t, J = 7Hz), 4.34-4.31 (1H,
m), 3.63 (6H, d, J = 11Hz), 3.39 (2H, d, J = 22Hz), 3.19-3.11 (1H,
m), 2.91-2.84 (1H, m); found: C, 55.73, H, 6.34; N, 6.80;
C₁₉H₂₇N₂O₆P requires C, 55.60; H, 6.63; N, 6.82%.

(c) 5-(3,5-Bistrifluoromethylphenyl)-2-t-butyloxy-carbonylamino-1-(3-indolyl)-4-penten-3-one

A solution of the product of part (b) (69.0g) in acetonitrile
25 (600ml) was stirred with diisopropylethylamine (43.3g), and
anhydrous lithium chloride (14.13g) for 30 minutes before
adding 3,5-bistrifluoromethylbenzaldehyde (55g) in acetonitrile
(200ml). The reaction was stirred for two hours then the solvent

was removed and the residue partitioned between ethyl acetate and water. The organic phase was washed with 10% citric acid (500ml), water (500ml), saturated sodium bicarbonate (500ml) and water (500ml). The solution was dried (MgSO_4), filtered and evaporated. The residue was purified by column chromatography on silica using ethyl acetate/petroleum ether (1:4) to yield the title compound as a pale yellow solid, mp = 137-138°C; found: C, 59.23; H, 4.79; N, 5.35; $\text{C}_{26}\text{H}_{24}\text{F}_6\text{N}_2\text{O}_3$ requires C, 59.32; H, 4.60; N 5.32%.

(d) 5-(3,5-Bistrifluoromethylphenyl)-2-t-butyloxy-carbonylamino-1-(3-indolyl)-3-pentanone

The product of part (c) was heated under reflux with tri-n-butyltin hydride (51.12g) in toluene for 20 hours. The reaction was cooled and purified by column chromatography on silica using ethyl acetate/petroleum ether (1:4) to yield the title compound as a white solid (37.1g), mp = 138-140°C: found: C, 59.23; H, 4.90; N, 5.28; $\text{C}_{26}\text{H}_{24}\text{F}_6\text{N}_2\text{O}_3$ requires C, 59.09, H, 4.96; N, 5.30%.

(e) 2-Amino-5-(3,5-bistrifluoromethylphenyl)-1-(3-indolyl)-3-pentanone Hydrochloride

The product of part (d) was treated with ethereal hydrogen chloride for one hour. The precipitated white solid was filtered and dried, mp = 84-86°C; found: C, 54.40; H, 4.25; N, 6.10; $\text{C}_{21}\text{H}_{18}\text{F}_6\text{N}_2\text{O} \cdot \text{HCl}$ requires C, 54.26; H, 4.12; N, 6.03%.

(f) N-(5-(3,5-Bistrifluoromethylphenyl)-1-(3-indolyl)-3-keto-
pent-2-yl)-succinamic acid Sodium salt

To a mixture of the compound of part (e) (215mg) and dichloromethane (3ml) cooled to -78°C under argon, was added
5 with stirring dry triethylamine (70µl). To the resulting solution was added succinic anhydride (50mg) and 4-dimethylaminepyridine (5mg), and the mixture was allowed to warm to room temperature. The mixture was stirred at room temperature for a further 3 hours before pouring into aqueous
10 2N hydrochloric acid (4ml). The organic layer was separated, and the aqueous layer extracted with ethyl acetate. The combined organic layers were dried (MgSO_4) and evaporated. The residue was treated with one equivalent of aqueous sodium hydroxide, sufficient acetonitrile added to render the mixture
15 homogeneous, and the resulting solution freeze dried. The resulting solid was dissolved in ethyl acetate (1ml) and petroleum ether (10ml) added. The mixture was boiled to half volume, and the solid product collected by filtration, and dried in-vacuo to afford the title compound. ^1H NMR (360MHz; D_6 -DMSO) δ 2.15 (2H, m), 2.25 (2H, m), 2.72 (1H, m), 2.87 (4H, m), 3.05 (1H, dd, $J=5.7, 14.5\text{Hz}$), 4.42 (1H, m), 6.97 (1H, t, $J=7.8\text{Hz}$), 7.05 (1H, t, $J=8.0\text{Hz}$), 7.18 (1H, d, $J=2.2\text{Hz}$), 7.32 (1H, d, $J=8.3\text{Hz}$), 7.48 (1H, d, $J=7.7\text{Hz}$), 7.79 (2H, s), 7.85 (1H, s), 9.00 (1H, d, $J=6.8\text{Hz}$), 10.90 (1H, s); m/e (CI^+) 528 (MH^+). Found: C, 52.12; H, 3.99; N, 4.67. $\text{C}_{25}\text{H}_{21}\text{F}_6\text{N}_2\text{O}_4\text{Na} \cdot 1.5(\text{H}_2\text{O})$ requires C, 52.00; H, 4.19; N, 4.85%.

EXAMPLE 25-(3,5-Bistrifluoromethylphenyl)-2-(4-carboxybutyramido)-1-(3-indolyl)-3-pentanone

5 To a solution of ethyl hydrogen glutarate (0.27g) in dimethylformamide (10ml) at 0°C, under an atmosphere of nitrogen, was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.32g). After stirring for 1 hour dichloromethane (10ml) was added followed by
10 triethylamine (0.15ml) and the compound of Example 1(e) (0.5g). After stirring for 16 hours the mixture was diluted with ethyl acetate, washed with water (3 x), dried and concentrated. After purification by chromatography on silica gel (eluant ethyl acetate-petroleum ether 1:1) the reaction product was dissolved
15 in tetrahydrofuran (5ml) and water (2ml) and treated with lithium hydroxide hydrate (100mg) for 16 hours. The solution was diluted with ethyl acetate, washed with 2N HCl, dried and concentrated. The residue in acetonitrile (5ml) was treated with
20 1N NaOH (0.9ml) and freeze dried to give the sodium salt of the title compound. ¹H NMR (360MHz, D₆-DMSO) δ 10.88 (1H, s), 8.30 (1H, d, J = 7.0Hz), 7.86 (1H, s), 7.80 (2H, s), 7.49 (1H, d, J = 7.8Hz), 7.32 (1H, d, J = 8.1Hz), 7.13 (1H, s), 7.06 (1H, t, J = 7.0Hz), 6.97 (1H, t, J = 7.9Hz), 4.50 (1H, m), 3.10-2.66 (6H, m), 2.13-2.06 (4H, m), 1.67-1.61 (2H, m). m/e 543 ([M+H]⁺, Cl⁺).

EXAMPLE 35-(3,5-Bistrifluoromethylphenyl)-2-(6-carboxyhexanamido)-1-(3-indolyl)-3-pentanone

5 The sodium salt of the title compound was prepared by the method of Example 2 using ethyl hydrogen pimelate. ¹H NMR (360MHz, D₆-DMSO) δ 11.04 (1H, s), 8.20 (1H, d, J = 7.2Hz), 7.86 (1H, s), 7.83 (2H, s), 7.49 (1H, d, J = 7.8Hz), 7.32 (1H, d, J = 8.0Hz), 7.12 (1H, s), 7.05 (1H, t, J = 7.0Hz), 6.96 (1H, t, J = 6.9Hz), 4.49 (1H, m), 3.10-2.70 (6H, m), 2.06-2.01 (4H, m), 1.39-1.35 (4H, m), 1.11-1.05 (2H, m). m/e 571 ([M+H]⁺, Cl⁺).

10

EXAMPLE 4

15 4-(3,5-Bistrifluoromethylphenyl)-2-(4-carboxybenzamido)-1-(3-indolyl)-3-pentanone

 The sodium salt of the title compound was prepared by the method of Example 2 using methyl terephthalate. Mp 272-274°C; ¹H NMR (360MHz, D₆-DMSO) δ 10.84 (1H, s), 8.81 (1H, s), 7.95 (2H, d, J = 8.2Hz), 7.86 (3H, s), 7.78 (2H, d, J = 8.2Hz), 7.57 (1H, d, J = 7.8Hz), 7.32 (1H, d, J = 8.1Hz), 7.19 (1H, d, J = 2.2Hz), 7.06 (1H, t, J = 7.0Hz), 6.98 (1H, t, J = 7.2Hz), 4.73 (1H, m), 3.35-3.22 (2H, m), 3.13-2.84 (4H, m). m/e 577 ([M+H]⁺, Cl⁺).

20

EXAMPLE 55-(3,5-Bistrifluoromethylphenyl)-2-(2-carboxybenzamido)-1-(3-indolyl)-3-pentanone

- 5 To a suspension of phthalic anhydride (0.16g) and the compound of Example 1(e) (0.5g) in dichloromethane (10ml) under nitrogen was added triethylamine (0.15ml) and 4-dimethylaminopyridine (5mg). After stirring for 16 hours 2N hydrochloric acid was added and extracted with
- 10 dichloromethane. The dichloromethane solution was dried, concentrated and the residue purified by chromatography on silica eluting with 10% methanol/dichloromethane. Crystallisation from diethyl ether/petroleum ether gave the title compound, mp 154-157°C; ^1H NMR (360MHz, D_6 -DMSO) δ
- 15 10.88 (1H, s), 7.84 (1H, s), 7.81 (2H, s), 7.62 (1H, d, J = 6.6Hz), 7.52-7.49 (2H, m), 7.39-7.27 (4H, m), 7.06 (1H, t, J = 7.9Hz), 6.98 (1H, t, J = 7.9Hz), 4.55 (1H, m), 3.14-3.07 (2H, m), 2.92-2.75 (4H, m). m/e 577 ($[\text{M}+\text{H}]^+$, Cl^+).

EXAMPLE 65-(3,5-Bistrifluoromethylphenyl)-2-(3-carboxybenzamido)-1-(3-indolyl)-3-pentanone

- 5 Prepared by the method of Example 2 using monobenzyl isophthalate with the exception that cleavage of the intermediate ester was effected by stirring in methanol-formic acid over palladium black under an atmosphere of nitrogen for 16 hours. The mixture was filtered, concentrated, chromatographed on
- 10 silica gel (10% methanol/dichloromethane) and crystallised from diethyl ether/petroleum ether to give the title compound, mp 113-116°C; ^1H NMR (360MHz, $\text{D}_6\text{-DMSO}$) δ 10.88 (1H, s), 8.42 (1H, s), 8.07 (1H, d, $J = 7.7\text{Hz}$), 7.97 (1H, d, $J = 7.8\text{Hz}$), 7.59-7.51 (2H, m), 7.32 (1H, d, $J = 8.1\text{Hz}$), 7.18 (1H, d, $J = 2.2\text{Hz}$), 7.06 (1H, t, $J = 7.0\text{Hz}$), 6.98 (1H, t, $J = 7.0\text{Hz}$), 4.74 (1H, m), 3.35-3.22 (2H, m), 3.14-2.80 (4H, m). m/e 577 ($[\text{M}+\text{H}]^+$, Cl^+).
- 15

EXAMPLE 7N-(3,5-Bis(trifluoromethyl)benzyl)-2-((4-pyridyl)acetamido)-3-(3-indolyl)propionamidea) N-(3,5-Bis(trifluoromethyl)benzyl)-2-amino-3-(3-indolyl)propionamide Hydrochloride

N- α -BOC-L-Tryptophan (12.6g) and triethylamine (8.36g) were dissolved in dichloromethane, cooled to -10°C, and treated with isobutylchloroformate. The reaction was stirred for 15 minutes before adding 3,5-bistrifluoromethylbenzylamine (10g), and stirring for 30 minutes at 0°C. The solvent was removed and the residue was taken up into ethyl acetate and washed with 10% citric acid (100ml), saturated sodium bicarbonate solution (100ml) and water (100ml). The organic phase was dried (MgSO₄) filtered and evaporated. The residue was dissolved in methanolic hydrogen chloride and stirred for 48 hours. The solvent was removed to yield the title compound (14.11g).

b) N-(3,5-Bis(trifluoromethyl)benzyl)-2-((4-pyridyl)acetamido)-3-(3-indolyl)propionamide

A suspension of 4-pyridylacetic acid (465mg) in dichloromethane (10ml) was treated with carbonyldiimidazole (245mg) and triethylamine (0.42ml) for 1.5 hours. The compound of Example 7a) (465mg) in dimethylformamide (5ml) was added and the solution was stirred for 3 hours then diluted with ethyl acetate, washed with sodium bicarbonate solution,

38

dried (Na_2SO_4) and concentrated. The residue was crystallised from ethyl acetate-diethyl ether to give the title compound, mp 227°C ; found: C, 58.84; H, 4.04; N, 9.95. $\text{C}_{27}\text{H}_{22}\text{F}_6\text{N}_4\text{O}_2$ requires C, 59.12; H, 4.04; N, 10.21.

5

EXAMPLE 8

N-(3,5-Bis(trifluoromethyl)benzyl)-2-((2-pyridyl)acetamido)-3-(3-indolyl)propionamide

Prepared by the method of Example 7 using 2-pyridylacetic acid. Mp $190-193^\circ\text{C}$; found C, 59.31; H, 4.05; N, 10.12. $\text{C}_{27}\text{H}_{22}\text{F}_6\text{O}_2\text{N}_4$ requires C, 59.13; H, 4.03; N, 10.22.

10

EXAMPLE 9

N-(3,5-Bis(trifluoromethyl)benzyl)-N-methyl-2-(3-(3-pyridyl)propionamido)-3-(3-indolyl)propionamide

15

a) N-(3,5-Bis(trifluoromethyl)benzyl)-N-methyl-2-amino-3-(3-indolyl)propionamide

20

Prepared by the method of Example 7(a) using N-methyl-3,5-bis(trifluoromethyl)benzylamine (prepared by dissolving 3,5-bis(trifluoromethyl)benzyl bromide in methanolic methyl amine solution)

25

39

b) N-(3,5-Bis(trifluoromethyl)benzyl)-N-methyl-2-(3-(3-indolyl)-propionamido)-3-(3-indolyl)-propionamide

5 3-(3-Pyridyl acetic acid) (0.15g), 1-[3-dimethylaminopropyl]-
3-ethylcarbodiimide hydrochloride (0.24g) and
hydroxybenzotriazole (0.14g) were stirred together in dimethyl
formamide (5ml) for two hours. The product of Example 9(a)
(0.4g) was added, followed by triethylamine (0.5ml). The
10 reaction was diluted with dichloromethane (5ml) and stirred for
16 hours. The reaction was diluted with ethyl acetate (50ml) and
washed with saturated sodium bicarbonate, and brine (5 x 50ml),
dried (MgSO₄), filtered, and evaporated to yield an oil, purified
by column chromatography on silica using
15 dichloromethane/methanol (99:1) to yield the title compound, mp
172-174°C; found: C, 60.42; H, 4.55; N, 9.72. C₂₉H₂₆F₆N₄O₂
requires C, 60.76; H, 4.47; N, 9.86%.

EXAMPLE 10


20 N-(3,5-Bis(trifluoromethyl)benzyl)-N-methyl-2-(4-(1-(1-azabicyclo[2.2.3]nonyl))butyramido)-3-(3-indolyl)propionamide

Prepared by the method of Example 9 using 4-(1-(1-
azabicyclo[2.2.3]nonyl))butyric acid, mp 140-142°C; found: C,
25 61.16; H, 5.79; N, 8.61. C₃₃H₃₈F₆N₄O₂·½H₂O requires C, 61.39; H,
6.09; N, 8.68%.

- 40 -

Claims:

1. A compound of formula (I), or a salt or prodrug thereof:



(I)


wherein

15 Q^1 represents a phenyl group substituted by one or more halo, optionally substituted naphthyl, optionally substituted indolyl, optionally substituted benzthiophenyl, optionally substituted benzofuranyl, optionally substituted benzyl, or optionally substituted
20 fluorenyl;

R^1 represents H or C_{1-6} alkyl;

R^2 represents H, C_{1-6} alkyl or C_{2-6} alkenyl;

Z^1 represents a group selected from



where one of X^1 and Y^1 represents H and the other represents hydroxy or C_{1-6} alkoxy, or X^1 and Y^1 together
35 form a group $=\text{O}$ or $=\text{NOR}^5$ where R^5 is H or C_{1-6} alkyl;

- 41 -

R^3 represents phenyl optionally substituted by 1, 2 or 3 groups selected from C_{1-6} alkyl, C_{1-6} alkenyl, C_{2-6} alkynyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, OR^a , SR^a , SOR^a , NR^aR^b , NR^aCOR^b , $NR^aCO_2R^b$, CO_2R^a or $CONR^aR^b$, where R^a and R^b independently represent H, C_{1-6} alkyl, phenyl or trifluoromethyl;

R^4 represents H or C_{1-6} alkyl;

the dotted line represents an optional covalent bond; and

when Z^1 represents a group of formula (a), Z^2 represents C_{1-6} alkyl CO_2H , phenyl or phenyl C_{1-4} alkyl, wherein each phenyl moiety is substituted by CO_2H ; and


when Z^1 represents a group of formula (b), Z^2 represents a group of the formula $-X^2-Y^2-R^6$; where

X^2 represents a bond, O, S or NR^7 , where R^7 is H or C_{1-6} alkyl;

Y^2 represents a bond or C_{1-6} alkylidene; and

R^6 represents NR^cR^d (where R^c and R^d each independently represent H, C_{1-6} alkyl, phenyl or phenyl C_{1-4} alkyl wherein each phenyl moiety may be substituted by one or more of C_{1-6} alkyl, C_{1-6} alkoxy, halo or trifluoromethyl) or an optionally substituted aromatic or non-aromatic azacyclic or azabicyclic group.

2. A compound as claimed in Claim 1 of formula (Ia) or a salt or prodrug thereof:



(Ia)

- 42 -

wherein

Q^1 represents a phenyl group substituted by one or more halo; optionally substituted naphthyl; optionally substituted indolyl; optionally substituted benzthiophenyl; optionally substituted benzofuranyl; optionally substituted benzyl; or optionally substituted fluorenyl;

the dotted line represents an optional covalent bond;

one of X^1 and Y^1 represents H and the other represents hydroxy or C_{1-6} alkoxy, or X^1 and Y^1 together form a group $=O$ or $=NOR^5$ where R^5 is H or C_{1-6} alkyl;


R^1 represents H or C_{1-6} alkyl;

R^2 represents H, C_{1-6} alkyl or C_{2-6} alkenyl;

R^3 represents phenyl optionally substituted by 1, 2, or 3 groups selected from C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, OR^a , SR^a , SOR^a , NR^aR^b , NR^aCOR^b , $NR^aCO_2R^b$, CO_2R^a or $CONR^aR^b$, where R^a and R^b independently represent H, C_{1-6} alkyl, phenyl or trifluoromethyl; and

Z^2 represents C_{1-6} alkyl CO_2H , phenyl or phenyl C_{1-4} alkyl, wherein each phenyl moiety is substituted by CO_2H .

3. A compound as claimed in Claim 1 of formula (Ib) or a salt or prodrug thereof:



(Ib)

wherein

- 43 -

Q^1 represents a phenyl group substituted by one or more halo, optionally substituted naphthyl, optionally substituted indolyl, optionally substituted benzthiophenyl, optionally substituted benzofuranyl, optionally substituted benzyl or optionally substituted fluorenyl;

X^2 represents a bond, O, S or NR^7 ;

Y^2 represents a bond or C_{1-6} alkylidene;

R^1 represents H or C_{1-6} alkyl;

R^2 represents H, C_{1-6} alkyl or C_{2-6} alkenyl;


R^3 represents phenyl optionally substituted by 1, 2, or 3 groups selected from C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, OR^a , SR^a , SOR^a , NR^aR^b , NR^aCOR^b , $NR^aCO_2R^b$, CO_2R^a or $CONR^aR^b$, where R^a and R^b independently represent H, C_{1-6} alkyl, phenyl or trifluoromethyl;

R^4 represents H or C_{1-6} alkyl;

R^5 represents H or C_{1-6} alkyl; and

R^6 represents NR^cR^d (where R^c and R^d each independently represent H, C_{1-6} alkyl or phenyl C_{0-4} alkyl optionally substituted in the phenyl ring by one or more of C_{1-6} alkyl, C_{1-6} alkoxy, halo or trifluoromethyl) or an optionally substituted aromatic or non-aromatic azacyclic or azabicyclic group.

4. A compound as claimed in either Claim 1 or Claim 2 of formula (Ic), or a salt or prodrug thereof:



(Ic)

- 44 -

wherein R^2 , X^1 and Y^1 are as defined for formula (I);
the dotted line represents an optional covalent bond;

5 Z² represents C₁₋₆alkylCO₂H, phenyl or
phenylC₁₋₄alkyl, wherein each phenyl moiety is
substituted by CO₂H;


Z^3 represents O, S or NR^{14} (where R^{14} is H, C_{1-6} alkyl, optionally substituted phenyl(C_{1-4} alkyl), CO_2R^a or $CONR^aR^b$, where R^a and R^b are as previously defined), preferably S or NH;

R^{11} and R^{12} each independently represent H, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, OR^a, SR^a, SOR^a, NR^aR^b, NR^aCOR^b, NR^aCO₂R^b, CO₂R^a or CONR^aR^b, where R^a and R^b are as previously defined;

each R¹³ may occupy any available carbon atom of the bicyclic ring system and independently represents C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, OR^a, SR^a, SOR^a, NR^aR^b, NR^aCOR^b, NR^aCO₂R^b, CO₂R^a or CONR^aR^b, where R^a and R^b are as previously defined; and

q is 0, 1, 2 or 3, preferably 0.

5. A compound as claimed in either Claim 1 or
25 Claim 3 of formula (Id), or a salt or prodrug thereof:



(1 d)

35 wherein x^2 and y^2 are as defined for formula (I);

- 45 -

Z^2 represents O, S or NR^{14} (where R^{14} is H, C_{1-6} alkyl, optionally substituted phenyl(C_{1-4} alkyl), CO_2R^a or $CONR^aR^b$, where R^a and R^b are as previously defined), preferably S or NH;

5 R^{10} is imidazolyl, triazolyl, tetrazolyl, oxazolyl, thiazolyl, pyrrolyl, pyrazolyl, pyrazinyl, pyridyl, oxadiazolyl, thiadiazolyl, isoxazolyl, isothiazolyl, benzimidazolyl, benzoxazolyl, indolyl, morpholinyl, piperdiny, pyrrolidinyl, piperazinyl, 10 methylpiperazinyl, azanorboranyl, azabicyclo[2.2.2]octanyl or azabicyclo[3.2.2]nonyl, preferably imidazolyl, pyridyl, morpholinyl, methylpiperazinyl, azabicyclo[2.2.2]octanyl or azabicyclo[3.2.2]nonyl;

15 R^{11} and R^{12} each independently represent H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, chloro, bromo, fluoro, iodo, cyano, nitro, trifluoromethyl, trimethylsilyl, OR^a , SR^a , SOR^a , NR^aR^b , NR^aCOR^b , $NR^aCO_2R^b$, CO_2R^a or $CONR^aR^b$, where R^a and R^b are as previously 20 defined;

each R^{13} may occupy any available carbon atom of the bicyclic ring system and independently represents C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, OR^a , SR^a , SOR^a , NR^aR^b , 25 NR^aCOR^b , $NR^aCO_2R^b$, CO_2R^a or $CONR^aR^b$, where R^a and R^b are as previously defined; and

q is 0, 1, 2 or 3, preferably 0.

30 6. A compound as claimed in Claim 1 wherein R^1 represents H or methyl.

7. A compound as claimed in Claim 1 wherein R^2 represents H or methyl.

35 8. A compound as claimed in Claim 1 wherein R^3 represents phenyl substituted by 1, 2 or 3 groups

- 46 -

selected from nitro, trifluoromethyl, trimethylsilyl, bromo, chloro, fluoro, iodo, cyano, methyl, ethyl, cyclopropyl, vinyl, methoxy, phenoxy and amino.

5 9. A compound as claimed in Claim 8 wherein R³ represents 3,5-bis(trifluoromethyl)phenyl.

10 10. A compound as claimed in Claim 1 wherein Q¹ represents a group selected from 3,4-dichlorophenyl, 3-indolyl, 2-naphthyl, 3-naphthyl, 9-fluorenyl, benzyl, 3-benzthiophenyl and 3-benzofuranyl.

15 11. A compound as claimed in Claim 1 wherein the double bond in the group of formula (a) is absent.

12. A compound as claimed in Claim 1 wherein X¹ and Y¹ in the group of formula (a) together represent =O.

20 13. A compound as claimed in Claim 1 wherein Z² represents the group C₁₋₃alkylCO₂H or phenyl substituted in the para position by CO₂H.

25 14. A compound as claimed in Claim 1 wherein R⁴ in the group of formula (b) represents H.

15. A compound as claimed in Claim 1 wherein X² represents a bond, O or NH.

30 16. A compound as claimed in Claim 1 wherein X² represents a bond and Y² represents CH₂.

35 17. A compound as claimed in Claim 1 wherein R⁶ represents a group selected from NR^CR^d (where R^C and R^d each independently represent H or C₁₋₆alkyl), imidazolyl, pyridyl, morpholinyl, methylpiperazinyl, quinuclidinyl and azabicyclo[3.2.2]nonyl.

- 47 -

18. A compound as claimed in Claim 17 wherein R⁶ represents 4-, 3-, or 2-pyridyl or quinuclidinyl.

19. A compound selected from

- 5 N-(5-(3,5-bis(trifluoromethyl)phenyl)-1-(3-indolyl)-3-pentanone-2-yl)-succinamic acid;
5-(3,5-bis(trifluoromethyl)phenyl)-2-(4-carboxybutyramido)-1-(3-indolyl)-3-pentanone;
5-(3,5-bis(trifluoromethyl)phenyl)-2-(6-carboxyhexanamido)-1-(3-indolyl)-3-pentanone;
10 5-(3,5-bis(trifluoromethyl)phenyl)-2-(4-carboxybenzamido)-1-(3-indolyl)-3-pentanone;
5-(3,5-bis(trifluoromethyl)phenyl)-2-(2-carboxybenzamido)-1-(3-indolyl)-3-pentanone;
15 5-(3,5-bis(trifluoromethyl)phenyl)-2-(3-carboxybenzamido)-1-(3-indolyl)-3-pentanone;
N-(3,5-bis(trifluoromethyl)benzyl)-2-((4-pyridyl)acetamido)-3-(3-indolyl)propionamide;
N-(3,5-bis(trifluoromethyl)benzyl)-2-((3-pyridyl)acetamido)-3-(3-indolyl)propionamide;
20 N-(3,5-bis(trifluoromethyl)benzyl)-N-methyl-2-(3-(3-pyridyl)propionamido)-3-(3-indolyl)propionamide;
N-(3,5-bis(trifluoromethyl)benzyl)-N-methyl-2-(4-(1-(1-azabicyclo[2.2.3]nonyl))butyramido)-3-(3-indolyl)propionamide;
25 or a salt or prodrug thereof.

20. A compound as claimed in any preceding claim for use in therapy.

30


21. A pharmaceutical composition comprising a compound as claimed in any one of Claims 1 to 19 in association with a pharmaceutically acceptable carrier.

- 48 -

22. A process for the preparation of a compound as claimed in Claim 1 wherein Z^1 represents a group of formula (a) which process comprises:

(A) reacting a compound of formula (II)


5



(II)

with a reagent suitable to introduce the group COZ^2 where Z^2 represents $C_{1-6}alkylCO_2H$, phenyl or phenyl $C_{1-4}alkyl$, wherein each phenyl moiety is substituted by CO_2H ; or
 (B) reacting a compound of formula (III)

15



(III)

with an aldehyde of formula R^3CHO , where R^{20} represents a group PR^X_3 or $PO(OR^X)_3$ wherein R^X represents phenyl or $C_{1-10}alkyl$;

and, if necessary or desired, converting the compound of formula (I) so prepared into another compound of formula (I), or a salt or prodrug thereof.


30

23. A process for the preparation of a compound as claimed in Claim 1 wherein Z^1 represents a group of


35

- 49 -

formula (b) which process comprises reacting a compound of formula (V) with a compound of formula (VI)



(V)



(VI)

- 15 wherein one of R^{22} and R^{23} represents a group CO-A , where
 A represents an activating group, and the other of R^{22}
 and R^{23} represents H;
 and, if necessary or desired, converting the compound of
 formula (I) so prepared into another compound of formula
 20 (I), or a salt or prodrug thereof.

24. A method for the treatment or prevention of
 physiological disorders associated with an excess of
 tachykinins, which method comprises administration to a
 25 patient in need thereof of a tachykinin reducing amount
 of a compound according to Claim 1, or a salt or prodrug
 thereof, or a composition comprising a compound according
 to Claim 1, or a salt or prodrug thereof.

- 30 25. A method according to Claim 24 for the
 treatment or prevention of pain or inflammation.

26. A method according to Claim 24 for the
 treatment or prevention of migraine.

- 50 -

27. A method according to Claim 24 for the treatment or prevention of emesis.

5 28. The use of a compound as claimed in Claim 1 for the manufacture of a medicament for the treatment of a physiological disorder associated with an excess of tachykinins.

10 29. The use of a compound as claimed in Claim 1 for the manufacture of a medicament for the treatment of pain or inflammation.

15 30. The use of a compound as claimed in Claim 1 for the manufacture of a medicament for the treatment of migraine.

 31. The use of a compound as claimed in Claim 1 for the manufacture of a medicament for the treatment of emesis.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 94/00438

A. CLASSIFICATION OF SUBJECT MATTER

IPC5: C07D 209/14, C07D 401/12, C07D 471/08, A61K 31/395
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC5: C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS-ONLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO, A1, 9301169 (MERCK SHARP & DOHME LIMITED), 21 January 1993 (21.01.93) --	1,3,5-12, 14-23,28-31
A	EP, A2, 0482539 (FUJISAWA PHARMACEUTICAL CO., LTD.), 29 April 1992 (29.04.92) --	1,3,5-12, 14-23,28-31
P,X	WO, A1, 9318023 (MERCK SHARP & DOHME LIMITED), 16 Sept 1993 (16.09.93) --	1-2,4,6-10, 12-13,15-16, 19-22,28-31

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents

A document defining the general state of the art which is not considered to be of particular relevance

B earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

& document member of the same patent family

Date of the actual completion of the international search

26 May 1994

Date of mailing of the international search report

13.06.94

Name and mailing address of the International Searching Authority



European Patent Office, P.B. 5818 Patentlaan 1.
NL-2280 HV Rijswijk
Tel (+31-70) 340-3040, Tx 31 651 epo nl
Fax (+31-70) 340-3016

Authorized officer

GÖRAN KARLSSON

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 94/00438

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E,A	WO, A1, 9401402 (MERCK SHARP & DOHME LIMITED), 20 January 1994 (20.01.94), see claim 1 -- -----	1-2,4,6-10, 12-13,15-16, 19-23,28-31

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 94/00438

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 24-28
because they relate to subject matter not required to be searched by this Authority, namely:
A method for treatment of the human or animal body by therapy, see Rule 39.1.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

07/05/94

International application No.

PCT/EP 94/00438

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO-A1-	9301169	21/01/93	CA-A-	2110514	21/01/93
			EP-A-	0593559	27/04/94
			AU-A-	2244092	11/02/93
			CA-A-	2110513	21/01/93
			CA-A-	2110725	21/01/93
			EP-A-	0522808	13/01/93
			EP-A-	0593557	27/04/94
			EP-A-	0593615	27/04/94
			WO-A-	9301159	21/01/93
			WO-A-	9301160	21/01/93
			WO-A-	9301165	21/01/93
			WO-A-	9409144	28/04/94
EP-A2-	0482539	29/04/92	AU-B-	647534	24/03/94
			AU-A-	8592591	30/04/92
			CN-A-	1060848	06/05/92
			JP-A-	4297492	21/10/92
WO-A1-	9318023	16/09/93	NONE		
WO-A1-	9401402	20/01/94	NONE		